Adage Capital Partners’s Akero Therapeutics AKRO Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-295,000	Closed	-$15.7M	–	875
2025 Q2	$15.7M	Buy	295,000 +100,000	+51%	+$4.54M	0.03%	507
2025 Q1	$7.89M	Buy	+195,000	New	+$8.27M	0.01%	632
2024 Q1	–	Sell	-275,000	Closed	-$6.42M	–	867
2023 Q4	$6.42M	Sell	275,000 -1,668,009	-86%	-$32.9M	0.01%	660
2023 Q3	$98.3M	Sell	1,943,009 -1,105,868	-36%	-$51.5M	0.22%	110
2023 Q2	$142M	Buy	3,048,877 +658,986	+28%	+$30.2M	0.31%	75
2023 Q1	$91.4M	Buy	2,389,891 +1,064,914	+80%	+$47.5M	0.21%	119
2022 Q4	$72.6M	Buy	1,324,977 +452,477	+52%	+$19.4M	0.17%	143
2022 Q3	$29.7M	Buy	+872,500	New	+$13.3M	0.07%	298
2020 Q1	–	Sell	-540,000	Closed	-$12M	–	724
2019 Q4	$12M	Buy	540,000 +15,000	+3%	+$310K	0.03%	501
2019 Q3	$11.9M	Buy	525,000 +428,279	+443%	+$9.97M	0.03%	485
2019 Q2	$1.85M	Buy	+96,721	New	+$1.83M	﹤0.01%	666